SG11201810935SA - Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals - Google Patents
Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicalsInfo
- Publication number
- SG11201810935SA SG11201810935SA SG11201810935SA SG11201810935SA SG11201810935SA SG 11201810935S A SG11201810935S A SG 11201810935SA SG 11201810935S A SG11201810935S A SG 11201810935SA SG 11201810935S A SG11201810935S A SG 11201810935SA SG 11201810935S A SG11201810935S A SG 11201810935SA
- Authority
- SG
- Singapore
- Prior art keywords
- basal insulin
- acid bearing
- carboxylate charges
- bearing carboxylate
- injectable solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI OF BETWEEN 5.8 AND 8.5 AND A COPOLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS [0001] The invention relates to physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, comprising at least: a) a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, and b) a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1655222A FR3052072A1 (en) | 2016-06-07 | 2016-06-07 | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACIDE CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS |
PCT/EP2017/063865 WO2017211903A1 (en) | 2016-06-07 | 2017-06-07 | Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810935SA true SG11201810935SA (en) | 2019-01-30 |
Family
ID=57348773
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810935SA SG11201810935SA (en) | 2016-06-07 | 2017-06-07 | Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals |
SG11201810937WA SG11201810937WA (en) | 2016-06-07 | 2017-06-07 | Injectable solution at ph 7, comprising at least one basal insulin whose pi is between 5.8 and 8.5, a prandial insulin and/or a gastrointestinal hormone, and a copolyamino acid bearing carboxylate charges and hydrophobic radicals |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810937WA SG11201810937WA (en) | 2016-06-07 | 2017-06-07 | Injectable solution at ph 7, comprising at least one basal insulin whose pi is between 5.8 and 8.5, a prandial insulin and/or a gastrointestinal hormone, and a copolyamino acid bearing carboxylate charges and hydrophobic radicals |
Country Status (12)
Country | Link |
---|---|
US (2) | US10548952B2 (en) |
EP (2) | EP3463292B1 (en) |
JP (1) | JP2019517555A (en) |
CN (2) | CN109379888B (en) |
BR (2) | BR112018075151A2 (en) |
EA (2) | EA039333B1 (en) |
FR (1) | FR3052072A1 (en) |
MX (2) | MX2018015068A (en) |
PH (1) | PH12018502558A1 (en) |
SA (2) | SA518400588B1 (en) |
SG (2) | SG11201810935SA (en) |
WO (2) | WO2017211916A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3070264A1 (en) * | 2017-08-24 | 2019-03-01 | Adocia | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN INCLUDING AN INHIBIT OF 5.8 TO 8.5 AND A CO-POLYAMINOACIDE CARBOXYLATE AND HYDROPHOBIC RADICAL CARRIERS |
FR3083089A1 (en) * | 2018-06-29 | 2020-01-03 | Adocia | PH 7 INJECTION SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARRYING CARBOXYLATES AND HYDROPHOBIC RADICALS |
MX2020005913A (en) | 2017-12-07 | 2020-10-19 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals. |
CN111683674A (en) | 2017-12-07 | 2020-09-18 | 阿道恰公司 | Composition in the form of an injectable aqueous solution comprising an amylin, an amylin agonist receptor or an amylin analog and a copoly amino acid |
KR20200106891A (en) | 2017-12-07 | 2020-09-15 | 아도시아 | A solution for injection at pH 7 comprising at least one basal insulin with a pI of 5.8 to 8.5, and a co-polyamino acid bearing a carboxylate charge and a hydrophobic radical |
FR3083086A1 (en) * | 2018-06-29 | 2020-01-03 | Adocia | COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID |
EP3740195A1 (en) * | 2017-12-07 | 2020-11-25 | Adocia | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid |
JP2021505605A (en) | 2017-12-07 | 2021-02-18 | アドシア | An injectable solution having a pH of 7 containing at least one basal insulin having a pI of 5.8 to 8.5 and a copolyamino acid having a carboxylate charge and a hydrophobic radical. |
WO2019115411A1 (en) * | 2017-12-07 | 2019-06-20 | Adocia | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a copolyamino acid |
FR3067247A1 (en) * | 2018-06-07 | 2018-12-14 | Adocia | COMPOSITIONS IN THE FORM OF AN INJECTION AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID |
WO2019243628A1 (en) * | 2018-06-22 | 2019-12-26 | Adocia | Injectable composition with a ph of 7 comprising a co-polyaminoacid bearing carboxylate charges and hydrophobic radicals and at least one basal insulin having at least a prandial effect and a basal effect |
FR3084585B1 (en) * | 2018-08-03 | 2020-11-06 | Adocia | SOLUTION FOR INJECTION AT PH 7 INCLUDING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS |
FR3084586B1 (en) * | 2018-08-03 | 2020-11-06 | Adocia | COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS |
US20200179489A1 (en) * | 2018-12-07 | 2020-06-11 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol |
WO2020115334A1 (en) * | 2018-12-07 | 2020-06-11 | Adocia | Method for preparing a stable composition in the form of an injectable aqueous solution |
WO2020245470A1 (en) | 2019-06-07 | 2020-12-10 | Adocia | Injectable solution at ph 7 containing at least one basal insulin, the pi of which is between 5.8 and 8.5, liraglutide, and a copolyamino acid carrying carboxylate charges and hydrophobic radicals |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985001890A1 (en) | 1983-10-26 | 1985-05-09 | Kanebo, Ltd. | Proteinous emulsifier, process for its preparation, and emulsified cosmetic preparation containing same |
DE3837825A1 (en) | 1988-11-08 | 1990-05-10 | Hoechst Ag | NEW INSULIN DERIVATIVES, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM |
FR2801226B1 (en) | 1999-11-23 | 2002-01-25 | Flamel Tech Sa | COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR VECTORIZATION OF ACTIVE INGREDIENTS AND METHOD OF PREPARATION |
PL374949A1 (en) | 2001-12-20 | 2005-11-14 | Eli Lilly And Company | Insulin molecule having protracted time action |
FR2840614B1 (en) | 2002-06-07 | 2004-08-27 | Flamel Tech Sa | POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS |
US20060217290A1 (en) | 2003-04-29 | 2006-09-28 | Kohn Wayne D | Insulin analogs having protracted time action |
FR2862535B1 (en) * | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | PHARMACEUTICAL FORMULATIONS FOR PROLONGED RELEASE OF INTERLEUKINS AND THEIR THERAPEUTIC APPLICATIONS |
FR2915683B1 (en) * | 2007-05-03 | 2009-08-07 | Flamel Technologies Sa | SELF-PRECIPITANT PHARMACEUTICAL FORMULATIONS FOR MODIFIED RELEASE OF ACTIVE INGREDIENTS |
CN103889442B (en) * | 2011-08-10 | 2016-12-28 | 阿道恰公司 | The Injectable solution of at least one basal insulin |
FR2985429B1 (en) | 2012-01-09 | 2016-07-29 | Adocia | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS |
WO2013104861A1 (en) | 2012-01-09 | 2013-07-18 | Adocia | Injectable solution having a ph of 7 and including at least basal insulin, the pi of which is between 5.8 and 8.5, and a substituted co-poly(amino acid) |
FR3001896B1 (en) | 2013-02-12 | 2015-07-03 | Adocia | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISO-ELECTRIC POINT IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIC ANIONIC POLYMER |
FR3001895B1 (en) | 2013-02-12 | 2015-07-03 | Adocia | PH7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISOELECTRIC POINT IS INCLUDED IN 5.8 AND 8.5 AND AN ANIONIC COMPOUND CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS |
-
2016
- 2016-06-07 FR FR1655222A patent/FR3052072A1/en not_active Withdrawn
-
2017
- 2017-06-07 US US15/616,470 patent/US10548952B2/en active Active
- 2017-06-07 MX MX2018015068A patent/MX2018015068A/en unknown
- 2017-06-07 WO PCT/EP2017/063886 patent/WO2017211916A1/en unknown
- 2017-06-07 CN CN201780035320.2A patent/CN109379888B/en active Active
- 2017-06-07 SG SG11201810935SA patent/SG11201810935SA/en unknown
- 2017-06-07 MX MX2018015067A patent/MX2018015067A/en unknown
- 2017-06-07 US US15/616,128 patent/US10383920B2/en active Active
- 2017-06-07 SG SG11201810937WA patent/SG11201810937WA/en unknown
- 2017-06-07 BR BR112018075151-0A patent/BR112018075151A2/en not_active Application Discontinuation
- 2017-06-07 JP JP2018564355A patent/JP2019517555A/en active Pending
- 2017-06-07 EA EA201892736A patent/EA039333B1/en unknown
- 2017-06-07 EP EP17727906.4A patent/EP3463292B1/en active Active
- 2017-06-07 EP EP17727910.6A patent/EP3463293B1/en active Active
- 2017-06-07 WO PCT/EP2017/063865 patent/WO2017211903A1/en unknown
- 2017-06-07 BR BR112018075140-5A patent/BR112018075140A2/en not_active Application Discontinuation
- 2017-06-07 EA EA201892737A patent/EA039363B1/en unknown
- 2017-06-07 CN CN201780047889.0A patent/CN109640953B/en active Active
-
2018
- 2018-12-04 SA SA518400588A patent/SA518400588B1/en unknown
- 2018-12-04 PH PH12018502558A patent/PH12018502558A1/en unknown
- 2018-12-05 SA SA518400596A patent/SA518400596B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
FR3052072A1 (en) | 2017-12-08 |
EA201892736A1 (en) | 2019-05-31 |
BR112018075151A2 (en) | 2019-03-26 |
SA518400588B1 (en) | 2022-03-07 |
CN109379888A (en) | 2019-02-22 |
EP3463292B1 (en) | 2020-08-05 |
EP3463292A1 (en) | 2019-04-10 |
SG11201810937WA (en) | 2019-01-30 |
EA039363B1 (en) | 2022-01-18 |
CN109640953A (en) | 2019-04-16 |
MX2018015067A (en) | 2019-05-09 |
JP2019517555A (en) | 2019-06-24 |
EA039333B1 (en) | 2022-01-14 |
SA518400596B1 (en) | 2022-03-16 |
CN109640953B (en) | 2021-10-29 |
EA201892737A1 (en) | 2019-05-31 |
MX2018015068A (en) | 2019-05-09 |
WO2017211903A1 (en) | 2017-12-14 |
EP3463293B1 (en) | 2021-05-12 |
BR112018075140A2 (en) | 2019-03-26 |
CN109379888B (en) | 2021-10-29 |
US10383920B2 (en) | 2019-08-20 |
PH12018502558A1 (en) | 2019-10-14 |
US10548952B2 (en) | 2020-02-04 |
WO2017211916A1 (en) | 2017-12-14 |
US20170348396A1 (en) | 2017-12-07 |
US20170348423A1 (en) | 2017-12-07 |
EP3463293A1 (en) | 2019-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA518400588B1 (en) | Injectable Solution at PH 7 Comprising at Least One Basal Insulin The PI of Which is From 5.8 to 8.5 and A Co-Polyamino Acid Bearing Carboxylate Charges and Hydrophobic Radicals | |
PH12020550827A1 (en) | Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals | |
SG11201810939PA (en) | Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid | |
WO2019110797A8 (en) | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid | |
MA46245A (en) | CYCLIC DINUCLEOTIDES AS AGONISTS (INTERFERON GENE STIMULATOR) | |
PH12020550828A1 (en) | Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid | |
BR112018010805A2 (en) | rsv f protein mutants | |
MX2014001190A (en) | Injectable solution of at least one type of basal insulin. | |
PH12020550804A1 (en) | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid | |
MY182507A (en) | Aqueous ophthalmic solution | |
SG11202005322RA (en) | Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals | |
PL3658115T3 (en) | Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor | |
MX2017015812A (en) | Injectable pharmaceutical formulations of lefamulin. | |
MX2018016339A (en) | Anti-infective heterocyclic compounds and uses thereof. | |
MX2016004328A (en) | Immunopotentiator. | |
EP4279577A3 (en) | Process | |
MX2021006187A (en) | Stable aqueous composition comprising oligosaccharides. | |
EA202091374A1 (en) | SOLUTION FOR INJECTION WITH pH 7, CONTAINING AT LEAST ONE BASAL INSULIN WITH pI BETWEEN 5.8 AND 8.5 AND COPOLYAMINO ACID CARBOXYLATE CARRIED OUT AND HYDROPHOBIC RADICALS | |
ZA202109597B (en) | Method for stabilizing the ph of an aqueous composition comprising a drug | |
FR3074681B1 (en) | PH 7 INJECTION SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARRYING CARBOXYLATES AND HYDROPHOBIC RADICALS | |
SG11201804902UA (en) | A composition for improving memory, learning ability, and cognitive ability | |
MX2017001900A (en) | Nasal composition comprising mixture of hyaluronic acids and saline solution. | |
MX2016010431A (en) | Compositions for preventing and/or treating pathological conditions associated with alpha-glucosidase. | |
GB2533749A (en) | Acid block and method of local acid treatment of subsea connecting element | |
PL410126A1 (en) | Method for obtaining a suspension of chitosan-silver nanoparticles and chitosan-silver nanocomposite |